Ticker

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM…

Bank of America Corp DE lifted its stake in Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 49.2% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,724 shares of the company's stock after purchasing an additional 170,417 shares during the period. Bank

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCETON, N.J., CAMBRIDGE, Mass., August 19, 2026 — Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3…

Taiho Oncology Inc., Taiho Pharmaceutical Co. Ltd., and Cullinan Therapeutics Inc. (NASDAQ:CGEM) on Thursday shared data from their global REZILIENT3 Phase 3 trial of zipalertinib in certain lung cancer patients.

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 — Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the…